AzTrials
AzTrials

Periodontal DiseasesNCT05858411

Clinical Effectiveness of Biologic Agents as an Adjunct to Non-surgical Periodontal Therapy of Intrabony Defects

A study testing SRP+rhPDGF, SRP+L-PRF and MINST alone in people with Periodontal Diseases and Periodontal Attachment Loss, run by G. d'Annunzio University at 1 site in Albania.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record

Search all trials

Trial summary

The aim of the present study is to clinically and radiographically compare the efficacy of recombinant human platelet-derived growth factor (rhPDGF), Leukocyte-Platelet Rich Fibrin (L-PRF) and Enamel Matrix Derivatives (EMD) in intrabony defects following minimally invasive non surgical peridoontal therapy (MINST). Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
SRP+rhPDGF, SRP+L-PRF and MINST alone
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
88 participants
Where
1 siteAlbania
Study dates
8 Jan 2023to 1 Sep 2027
Phase
Interventional

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients with a diagnosis of periodontitis stage III or IV (grades A to C),
  • non-smokers or former smokers who quit at least 1 year ago, and
  • had not received any periodontal treatment in the 3 months prior to recruitment;
  • Presence of at least 1 Infrabony defect (PPD ≥ 5 mm with infrabony defect depth of ≥3mm at screening radiograph);
  • One and two wall infrabony defects at screening radiograph and periodontal charting.
  • Signed informed consent.

Who cannot join

  • Presence of uncontrolled systemic diseases that could affect treatment outcomes such as diabetes mellitus with an HbA1C>7%, rheumatoid arthritis or any form of immunosuppression;
  • Subjects requiring antibiotic prophylaxis;
  • 3-wall infrabony defects;
  • Patients that had received systemic or local delivery of antibiotic therapy 6 weeks before enrollment;
  • Presence of furcation defect;
  • Chronic intake of NSAIDs or steroids, currently;
  • Patients undergoing orthodontic treatment, having removable prosthetic appliances, pregnancy, tumors of the oral cavity or the presence of any psychiatric condition that could affect participation.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Michele Paolantonio, DDS, MD contact

3395204073

michelepaolantonio@gmail.com

Albania1 site, 1 recruiting
  • University of Medicine of Tirana

    Tirana

    Recruiting

Other trials in Albania

About this study

Official title: Evaluation of the Efficacy of rhPDGF, L-PRF and EMD as an Adjunct to Non-surgical Periodontal Therapy of Intrabony Defects: a Randomized Controlled Clinical Trial

The aim of the present study is to clinically and radiographically compare the efficacy of recombinant human platelet-derived growth factor (rhPDGF), Leukocyte-Platelet Rich Fibrin (L-PRF) and Enamel Matrix Derivatives (EMD) in intrabony defects following minimally invasive non surgical peridoontal therapy (MINST).

This study will be designed as a randomized clinical trial of 12-month duration. A total of 88 patients (each with a single infrabony defect) will be recruited and randomly equally distributed into 4 groups: an experimental group treated with MINST and rhPDGF, a second group treated with MINST + L-PRF, a third group treated with MINST and EMD and and a control group treated with MINST alone.

Read more

Each defect will be treated with an ultrasonic scaler with dedicated thin tips for supra- and subgingival debridement associated with hand instrumentation under local anesthesia. Caution will be taken to preserve the stability of soft tissues. Following MINST experimental and control sites will be randomly chosen. The test sites will be treated by inserting a collagen plug soaked for at least 15 minutes in a 1.5cc solution containing hPDGF-BB. In the second group the infrabony defects will be treated with MINST and L-PRF. In the third group the infrabony defects will be treated with MINST and EMD. The control group will be treated with MINST alone.

Pre- and post-treatment clinical measurements were performed by an examiner blinded to the treatment modalities using a graded periodontal probe (HuFriedy UNC 15). Before the treatment and at 6 and 12 months post-treatment, all patients were examined by measuring the clinical attachment level, probing depth, gingival recession, full-mouth plaque score and bleeding on probing.

Standardized radiographs of selected study sites will be taken at baseline and at the 6 and 12 months follow-up visits using the long-cone technique with a customized holder and a thermoplastic occlusal reference to allow reproducible positioning. All radiographs will be analysed by a dedicated dental software (Carestream Dental LLC Atlanta, GA, USA) to make linear measurements. The defect bone level (DBL), the defect angle (DA), the intra- and suprabony components of the defect and the radiographic defect area (RDA) will be evaluated.

Being tested
SRP+rhPDGF, SRP+L-PRF, MINST alone, MINST+EMD
Keywords
rhPDGF, Growth factors, Periodontal regeneration, L-PRF, Enamel Matrix Derivatives
Medical subject headings
Periodontal Diseases, Periodontal Attachment Loss, Periodontal Pocket

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • SRP+rhPDGFProcedure or surgery

    The infrabony defect will be debrided with the use of fine ultrasonic tips and mini hand instruments and will be treated with the application of a collagen sponge soaked in rhPDGF.

  • SRP+L-PRFProcedure or surgery

    The infrabony defect will only be debrided with the use of fine ultrasound tips and mini hand instruments and will be treated with the application of a L-PRF membrane.

  • MINST aloneProcedure or surgery

    The infrabony defect will only be debrided with the use of fine ultrasound tips and mini hand instruments and no further treatment will be performed.

  • MINST+EMDProcedure or surgery

    The infrabony defect will only be debrided with the use of fine ultrasound tips and mini hand instruments and will be treated with the application of EMD gel.

Study groups in NCT05858411
Study groupRoleWhat they receive
MINST+rhPDGFExperimentalAfter MINST the infrabony defect will be filled with a collagen sponge soaked in rhPDGF.
Receives: Procedure: SRP+rhPDGF
MINST+ L-PRFActive comparatorAfter MINST the infrabony defect will be filled with a L-PRF membrane.
Receives: Procedure: SRP+L-PRF
MINST aloneActive comparatorMINST alone will be performed.
Receives: Procedure: MINST alone
MINST+EMDActive comparatorAfter MINST the infrabony defect will be filled with EMD gel.
Receives: Procedure: MINST+EMD

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Defect Bone Level (DBL)

    Distance between the cemento-enamel junction (CEJ) and the bottom of the defect (BD)

    Measured: 12 months

  2. Clinical Attachment Level (CAL)

    Distance between the CEJ and the bottom of the pocket

    Measured: 12 months

Secondary outcomes (4)
  1. Pocket Probing Depth (PPD)

    Distance between the gingival margin and the bottom of the pocket.

    Measured: 12 months

  2. Gingival Recession (GR)

    Distance between the CEJ and the gingival margin.

    Measured: 12 months

  3. Defect Angle (DA)

    Angle between the long axis of the tooth and the interproximal wall of the infrabony defect.

    Measured: 12 months

  4. Radiographic Defect Area

    Area of the triangle defined by: side passing through the top of the interproximal ridge and perpendicular to the long axis of the tooth, side passing through the bottom of the defect and the intersection of the previous side with the root of the tooth, side passing through the top of the ridge and the bottom of the defect.

    Measured: 12 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 May 2023
  2. Study start8 Jan 2023
  3. Primary completion1 Sep 2027 (estimated)
  4. Study completion1 Sep 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Outcomes assessor
Enrolment
88 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05858411
Sponsor's protocol ID
21042023
Status last verified
May 2026
First submitted
21 Apr 2023
Last updated
28 May 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in